No evidence of enhanced oxidant production in blood obtained from patients with obstructive sleep apnea

Table 5 Luminol enhanced whole blood chemiluminescence (LBCL) measured before and after polysomnography controlled sleep

		Patients undergoing polysomnography
Chemiluminescence parameter	Time of the day	OSAS	Severe OSAS	CPAP-OSAS	Controls
rCL [aU/10⁴p]	Evening	2.4 ± 2.2	1.9 ± 1.8	2.2 ± 1.9	1.9 ± 1.8
	Morning	2.3 ± 2.2	2.5 ± 2.8	1.5 ± 0.9	1.6 ± 1.5
	Diff and 95% CI	0.1 (-0.7 – 0.8)	0.6 (0.15 – 1.02)	0.7 (0.1 – 1.2)	0.2 (-0.1 – 0.5)
pCL [aU/10⁴p]	Evening	6.4 ± 5.1	4.9 ± 4.7	6.0 ± 4.4	5.5 ± 4.3
	Morning	5.9 ± 4.6	5.9 ± 4.8	4.3 ± 2.9	4.7 ± 2.5
	Diff and 95% CI	0.5 (-0.9 – 1.8)	0,9 (-0.4 – 2.2)	1.6 (0.4 – 2.9)	5.2 (-2,0 – 12.4)
tCL [aU·s/10⁴p]	Evening	1939 ± 1532	1503 ± 1391	1805 ± 1278	1642 ± 1316
	Morning	1790 ± 1371	1778 ± 1442	1313 ± 820	1416 ± 961
	Diff and 95% CI	149 (-275 – 573)	275 (-117 – 668)	492 (132 – 852)	225 (22 – 430)
Peak time [s]	Evening	281 ± 31	276 ± 37	293 ± 30	270 ± 24
	Morning	275 ± 30	277 ± 37	284 ± 22	339 ± 23
	Diff and 95% CI	6 (0.3 – 11.5)	1 (-5.3 – 6.5)	9 (0.1 – 16.3)	69 (-22 – 160)

rCl – the average resting chemiluminescence prior to addition of fMLP; pCL – maximal chemiluminescence signal after addition of fMLP; tCl – total light emission after cell stimulation with fMLP; peak time – the time from fMLP addition to the appearance of pCL; OSAS – patients with the untreated OSAS; Severe OSAS – patients with AHI ≥ 30; CPAP-OSAS – patients with OSAS treated successfully after a first attempt with CPAP, controls – subjects without OSAS Results expressed as mean ± SD, difference of means with 95% confidence interval (Diff and 95% CI) No significant differences (p > 0.05) were found for evening and morning LBCL parameters within and between the studied groups.

ISSN: 1477-5751